Ribonucleotide reductase inhibitor
This page covers all Ribonucleotide reductase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Ribonucleotide reductase.
Targets
Phase 3 pipeline (6)
- Hydroxyurea treatment (HU) · Assistance Publique - Hôpitaux de Paris · Hematology/Oncology
Hydroxyurea inhibits ribonucleotide reductase to reduce DNA synthesis and increase fetal hemoglobin production, reducing sickling and hemolysis. - Hydroxycarbamide Tablets · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Oncology; Hematology
Hydroxycarbamide inhibits ribonucleotide reductase, reducing deoxynucleotide synthesis and promoting fetal hemoglobin production while decreasing sickling and hemolysis. - Low Dose Hydroxyurea · Vanderbilt University Medical Center · Hematology/Oncology
Low-dose hydroxyurea increases fetal hemoglobin (HbF) production and reduces sickling of red blood cells by inhibiting ribonucleotide reductase. - Hydroxyurea (Low Dose) · Vanderbilt University Medical Center · Hematology/Oncology
Low-dose hydroxyurea increases fetal hemoglobin (HbF) production and reduces sickling of red blood cells by inhibiting ribonucleotide reductase. - Moderate Dose Hydroxyurea · Vanderbilt University Medical Center · Hematology/Oncology
Hydroxyurea inhibits ribonucleotide reductase to reduce DNA synthesis and increase fetal hemoglobin production, thereby reducing sickling and hemolysis. - Hydroxyurea (Moderate Dose) · Vanderbilt University Medical Center · Hematology/Oncology
Hydroxyurea inhibits ribonucleotide reductase to reduce DNA synthesis and promote fetal hemoglobin production.